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Hepatitis C virus (HCV) often establishes a persistent infection that leads to chronic liver diseases.
The viral core protein modulates various cellular activities involved in this process. We found two
mutations, K23E and V31A, in the core gene of the transfected HCV JFH-1 genome, which had been
replicated for a prolonged period. The mutant viruses escaped immunochemical detection by a core-
speciﬁc antibody and demonstrated enhanced RNA replication and protein expression, compared to
the parental virus. The mutant core proteins bound less tightly than the parental type core to the
DEAD-box RNA helicase DDX3 and attenuated the TBK1-mediated activation of interferon-related
promoters. These results suggest a mechanism by which the viruses adapt to attenuate cellular anti-
viral activity and to establish persistent infection.
Structured summary of protein interactions:
DDX3 and CORE colocalize by ﬂuorescence microscopy (View Interaction: 1, 2, 3)
DDX3 physically interacts with CORE by two hybrid (View Interaction: 1, 2, 3)
CORE physically interacts with DDX3 by pull down (View Interaction: 1, 2, 3)
 2012 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Hepatitis C virus (HCV) is a leading cause of liver disease,
including liver cancer. More than 170 million people are currently
infected with HCV worldwide. As a member of the Flaviviridae, the
9.6-kb long, single-stranded, positive-sense RNA genome of HCV
codes for a polyprotein precursor of approximately 3000 amino
acids, which is co-translationally processed into the core, envelope
1 (E1), E2, p7, non-structural protein 2 (NS2), NS3, NS4A, NS4B,
NS5A and NS5B proteins. The HCV core protein (amino acids
1–191) binds the viral RNA to form the viral nucleocapsid
(reviewed by Moradpour et al.) [1]. A patient-derived viral clone
(JFH-1) that replicated and spread in human hepatoma cells
recently made it possible to study the entire HCV replication cycle
[2–4]. Serial passage of the HCV in culture has yielded adapted
viruses with enhanced infectivity [5–7].
Interferon (IFN) is the primary defense against viral infection.
Triggered by viral infection, host cells produce IFN-a and IFN-b. Se-
creted IFNs bind their cognate receptors and activate the Jak-1 and
Tyk-2 kinases, which leads to the phosphorylation of the STAT-1
and STAT-2 proteins. Binding of the activated STATs, in combina-
tion with the IRF9 to the IFN-stimulated response element (ISRE)on behalf of the Federation of Euro
, Sungbuk, Seoul 136-701,
.activates the promoters of plethora of genes called the IFN-stimu-
lated genes (ISGs), including those with antiviral activities [8]. Con-
siderable evidence exists for the activation of the IFN system in
HCV infection. Elevated levels of ISGs (MxA & OAS) were reported
in the serum and peripheral blood cells of chronic hepatitis C pa-
tients compared to healthy controls [9,10]. In addition, activation
of IRF3 was found early in HCV infection [11,12]. Virus-induced
activation of host IFN-a/b response would be limiting viral infec-
tion; however, the mechanism by which HCV activates the IFN
pathway has not been elucidated. HCV RNA is considered to be
the main pathogen-associated molecule that is recognized by the
RIG-I helicase for the induction of IFN signaling [13]. Ectopic
expression of the HCV core protein increased the OAS1 mRNA (2
to 6-fold) and a transfected reporter gene that carried the OAS1
gene promoter [14]. In contrast to the IFN-activating effect of
HCV, IFN-blockading mechanisms of HCV had been also known
[15].
HCV core protein interacts with DDX3, the DEAD-box RNA heli-
case that is implicated in diverse cellular processes [16]. DDX3 was
demonstrated to be required for HCV replication [17]. DDX3 binds
at the N-terminus of the core protein and co-localizes with the core
in lipid droplets. However, mutations at this region of the core had
no effect on viral replication despite abrogated DDX3 binding [18].
Therefore, the interaction between DDX3 and the core is unrelated
to its essential role in viral replication. DDX3 interacts with TBK1/
IKKe and activates IRF3 in the IFN pathway [19]. A recent reportpean Biochemical Societies.
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signaling for IFN-b induction [20].
In this study, we found that mutations that were generated in
the core protein of the JFH-1 virus during successive passage atten-
uated the type I IFN pathway. The activity of the core mutants was
correlated with their differential interaction with DDX3. These
mutations rendered an enhancement of viral RNA replication and
protein expression, which suggests a mechanism by which HCV
establishes persistent infection.2. Materials and methods
2.1. Cells and viruses
Human hepatoma Huh-7 and Huh-7.5 (kindly provided by C.
Rice) cells were grown in Dulbecco’s Modiﬁed Eagle’s Medium sup-
plemented with 25 mM HEPES, 50 lg/ml of gentamicin and 5% fe-
tal bovine serum (Invitrogen) at 37 C in 5% CO2. The cells were
electroporated with the in vitro synthesized RNA of HCV JFH-1
(genotype 2a) or that of the core mutants by using the Gene Pulser
II RF module (Bio-Rad) as previously described [21]. Transfected
cells were split at intervals of 3–6 days. The viral titer in the culture
supernatant was determined by the focus-forming assay: the Huh-
7.5 cells were grown in 96-well plates, infected with serially di-
luted virus stock and immunostained 3 days later for the NS5A
protein. Lipofectamine (Invitrogen) was used for the transfection
of cells with DNA.
2.2. Plasmids
The core (1–191 amino acids) coding sequence of JFH-1 was
ampliﬁed and inserted with the N-terminal HA epitope into the
HindIII-EcoRI sites of the expression vector pHM6 (Roche). The mu-
tant core clones K23E, V31A and K23E/V31A were generated by
two-step PCR. The core sequences were subcloned into the SgfI-
PmeI sites of the pFN21A-HaloTag CMV Flexi Vector (Promega)
for N-terminal HaloTag labeling, or inserted into the HindIII-NotI
sites of pCMV-AD (Stratagene) downstream of the N-terminal NF-
jB activation domain for the mammalian two-hybrid assay. DDX3
(kindly provided by N.H. Cho) was subcloned into p3xFLAG-CMV-
10 (Sigma), which contained three copies of Flag at the N-terminus,
or it was inserted into pCMV-BD (Stratagene) downstream of the
Gal4 DNA binding domain for the mammalian two-hybrid assay.
The ﬁreﬂy luciferase reporter pIFNb-Luc (kindly provided by J.W.
Oh) contained two copies of a 282-bp interferon-b promoter. The
reporter plasmids pISRE-Luc and pFR-Luc (from Stratagene) con-
tained ﬁve copies of an ISRE (tAGTTTCACTTTCcc) of ISG54 and ﬁve
copies of a Gal4-binding sequence, respectively. The renilla lucifer-
ase reporter pRL-TK was used as a normalizing control in the Dual-
Luciferase Reporter Assay System (Promega). TBK1 (kindly pro-
vided by M.J. Song) was subcloned into p3xFLAG-CMV-10.
2.3. Immunoblotting
The virus-infected and transfected cells were lysed in RIPA buf-
fer (10 mM Tris–HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 0.5% Tri-
ton X-100, 0.1% SDS and 0.25% sodium deoxycholate)
supplemented with protease inhibitors (1 mM PMSF, 1 lg/ml leu-
peptin and 4 lg/ml aprotinin). The proteins were separated by a
denaturing polyacrylamide gel and transferred to a Hybond ECL
membrane (GE Healthcare). The blots were incubated with anti-
bodies in TBST buffer (20 mM Tris–HCl [pH 7.6], 137 mM NaCl
and 0.1% Tween-20) containing 5% skim milk, washed with TBST
buffer and visualized with the SuperSignal West Pico Chemilumi-
nescent reagents (Thermo Scientiﬁc). Rabbit polyclonal antibodiesto NS5A and NS5B were raised with recombinant proteins ex-
pressed in Escherichia coli. The core-speciﬁc monoclonal antibody
(MA1–080, c7–50) was from Afﬁnity BioReagents (Golden, CO).
The anti-HA (H6908), anti-Flag (F3165) and anti-tubulin (T9026)
antibodies were from Sigma. The anti-GAPDH (sc-47724) antibody
was from Santa Cruz Biotechnology. The anti-HaloTag antibody
was from Promega.
2.4. Viral RNA analysis
The HCV RNA was extracted from the supernatant of virus-in-
fected cells with the QIAamp Viral RNA Mini Kit (Qiagen, Valencia,
CA) and converted to DNA with Improm II Reverse Transcriptase
(Promega) and the JFH1–1R primer (50-TGCCA AGCTG CCACG AA-
GAA-30). The core coding sequence was ampliﬁed with PrimStarTM
DNA Polymerase (Takara, Japan) and the primers JFH1-SF (50-CAT-
AG TGGTC TGCGG AAC-30) and JFH1–1R. The ampliﬁed DNA was
directly sequenced with JFH1-SF by using the ABI 3730 Genetic
Analyzer (Applied Biosystems, Foster City, CA). For the northern
blot analysis of viral RNA, total RNA was extracted from viral
RNA-transfected cells (4  106 cells) using RNAiso™ Plus (Taka-
ra). The RNA (10 lg) was separated in 1% agarose gel containing
formaldehyde, transferred to a Nytran membrane (Schleicher &
Schuell, Keene, NH), irradiated with UV at 20,000 lJ/cm2 (UVP
Inc., San Gabriel, CA) and probed with 32P-labeled NS5A DNA (nt
6273–7110) in a hybridization solution (7% SDS, 1 mM EDTA,
0.5 M sodium phosphate, pH 7.2). The probe was labeled with
[a-32P] dCTP by using a random prime kit (Takara, Japan).
2.5. Pull-down and two-hybrid assays
The interaction between the Flag-tagged DDX3 and the core,
which was fused to the Halo Tag protein (Promega), was measured
in a pull-down assay. Huh-7 cells were co-transfected with the two
constructs, harvested, frozen at 80 C for 30 min, resuspended in
300 ll of Mammalian Lysis buffer containing 1 Protease Inhibitor
Cocktail (Promega) and incubated on ice for 5 min. After centrifu-
gation at 14000g for 5 min at 4 C, the supernatant was diluted
with 700 ll of 1 TBS and incubated overnight at 4 C with
100 ll of HaloLink Resin (Promega) with inverted mixing. The res-
ins were washed with 0.5 ml of 0.05% NP-40 in TBS, resuspended in
50 ll of SDS elution buffer and incubated for 30 min at room tem-
perature with shaking. After the resin was removed by centrifuga-
tion, the supernatant was immunoblotted for DDX3. In the two-
hybrid assay, DDX3 was fused to Gal4 DNA-binding domain; the
core was fused to the NF-jB activation domain; and both DDX3
and the core were co-transfected with the Gal4-responsive pFR-
Luc and pRL-TK. The ﬁreﬂy enzyme activity was measured in
48 h and normalized with the renilla enzyme activity.
2.6. Fluorescence imaging
Huh-7 cells were grown on coverslips and transfected with
Flag-tagged DDX3 and HaloTag-fused core genes. At 48 h, the cells
were incubated with a 1:2000 diluted HaloTag TMR Ligand (Pro-
mega) for 6 h at 37 C in 5% CO2. The cells were washed with cold
PBS, ﬁxed in 4% paraformaldehyde and 0.2% sucrose in PBS for
10 min, permeabilized with 0.1% Triton X-100 in PBS and washed
with PBS. DDX3 was immunostained with the anti-Flag antibody
(1:1000 dilution) in blocking buffer (PBS containing 1% BSA and
0.1% Tween-20) for 2 h at 37 C, followed by incubation with
FITC-conjugated sheep anti-mouse IgG (F-3008, Sigma) for 1 h at
37 C. The cells were further stained with 1 lg/ml DAPI for
1 min, mounted with FluoroGuard Antifade (Bio-Rad, Hercules,
CA) and observed under a confocal laser scanning microscope
(LSM 510 META, Carl Zeiss).
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Huh-7 cells were co-transfected with the HA-tagged core and
Flag-tagged DDX3. At 48 h, the cells were harvested and cellular
proteins were fractionated as previously described [22]. Brieﬂy,
the cells were resuspended in 300 ll of 0.5% Triton X-100 lysis buf-
fer (50 mM Tris–HCl [pH 7.5], 137.5 mM NaCl, 5 mM EDTA, 0.5%
Triton X-100, 10% glycerol, 1 mM sodium vanadate, 50 mM sodium
ﬂuoride, 10 mM sodium pyrophosphate and 1 mM PMSF), incu-
bated on ice for 15 min and centrifugated at 13,000 rpm for
15 min at 4 C. The supernatant (containing the membrane and
cytoplasmic fractions) was transferred into a new tube. The
remaining materials (nuclear and other insoluble) in the pellet
were resuspended in lysis buffer containing 0.5% SDS and brieﬂy
sonicated to shear cellular DNA. Each fraction was immunoblotted
for the core and DDX3. A membrane ﬂotation assay was performed
as previously described [23]. Brieﬂy, the transfected cells were ﬁrst
lysed in 0.6 ml of hypotonic buffer (10 mM Tris–HCl, pH 7.5,
10 mM KCl and 5 mM MgCl2), passed through a 26-gauge needle
20 times, supplemented with NP-40 at 1% and incubated on ice
for 20 min. The nuclei and unbroken cells were removed by centri-
fugation at 1000g for 5 min at 4 C. The supernatant (0.5 ml) was
mixed with 3 ml of 72% sucrose in low salt buffer (50 mM Tris–HClNS5B
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Fig. 1. Antigenic alterations of the core protein occurred during the long-term
subculturing. (A) Huh-7 and Huh-7.5 cells were infected (moi of 0.2) with D35 or
D158 virus samples and immunoblotted three days later for the NS5A, NS5B and
core proteins. The D35 and D158 virus samples were obtained from the culture
supernatant of JFH-1 RNA-transfected Huh-7 cells that had been subcultured at
intervals of 3–6 days for 35 and 158 days, respectively. Tubulin was probed as a
loading control. Note that the core was not detected in the D158 sample. (B) The
core coding sequence of the D158 virus was ampliﬁed and sequenced. Two
missense mutations, K23E (AAG to GAG) and V31A (GUU to GCU), were detected as
indicated. Note that the parental-type sequence was still detected in the ﬁrst
nucleotide position of codon 23. (C) The N-terminally HA-tagged core of JFH-1 and
the mutants were transfected into Huh-7 cells and immunoblotted with anti-core
and anti-HA antibodies.[pH 7.5], 25 mM KCl and 5 mM MgCl2) in a tube and overlaid suc-
cessively with 4 ml of 55% sucrose and 1.5 ml of 10% sucrose in the
buffer. The sample was centrifuged at 38,000 rpm in a Beckman
SW41Ti rotor for 14 h at 4 C and fractions of 0.75 ml were col-
lected. The core and DDX3 in the fractions were immunoblotted.3. Results
3.1. Antigenic alteration of the core protein in a culture-adapted virus
Infectious HCV can be produced from viral RNA that is transfec-
ted into human hepatoma cell culture. Serial passage of HCV in cell
culture has led to the isolation of adapted viruses with enhanced
infectivity. We reported a biphasic increase of viral infectivity dur-
ing the serial passage of JFH-1 RNA-transfected Huh-7 cells. When
the transfected cells were successively split at three-day intervals,
the percentage of infected cells gradually increased to almost 100%
around day 35, decreased by day 75, increased again to approxi-
mately 100% of the cells by day 100 and stayed likewise [21]. To
determine the cause of the infectivity change, the virus samples,
which were obtained from the culture supernatant on days 35
and 158 (referred to as the D35 and D158 samples, respectively),
were further ampliﬁed and inoculated to the Huh-7 and Huh7.5
cells. Interestingly, the immunoblot demonstrated that the viral
NS5A, NS5B and core proteins were detected in the D35 sample;
however, the core protein of D158 sample was not detected with
a core-speciﬁc antibody (Fig. 1A). A similar result was obtained
in immunostained cells (data not shown). To identify the molecular
basis of this ﬁnding, the core coding sequence of D158 was ampli-vRNA
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Fig. 3. Activation of the IFN-b and the ISRE promoters by the core. (A) IFN-b promoter-controlled luciferase pIFNb-Luc was transfected into HCV RNA-transfected Huh-7 cells
and the enzyme activity was measured 24 h later. (B, C) Luciferase activity was measured 48 h after co-transfection of the core and pIFNb-Luc or pISRE-Luc. The renilla
luciferase reporter pRL-TK was co-transfected as a control. In several samples, TBK1 was co-transfected in addition to the core. The mean value of the fold-induction from the
triplicate assays is shown.
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missense mutations in the N-terminal domain of the core, K23E
(AAG to GAG) and V31A (GUU to GCU) (Fig. 1B). The immunoblot
analysis of the core-transfected cells indicated that the V31Amuta-
tion caused the antigenic alteration (Fig. 1C). This result is in accor-
dance with the reported epitope (aa 21–40) for the core antibody
(c7–50) that we used [24]. The K23 and V31 residues are conserved
in all of the HCV genotypes. Our retrospective analysis on the virus
samples obtained at additional time points indicated that V31A
was not detected in the D61 sample until it appeared as a minor
species in the D92 sample, suggesting that this mutation have oc-
curred during the second infectivity rise (started around day 75).
K23E was not detected in the D158 sample and appeared as a min-
or species during the ampliﬁcation of the D158 sample (data not
shown).
3.2. Enhanced replication of the core mutants
To characterize the effect of the core mutations on viral replica-
tion, we introduced each or both of the K23E and V31A mutationsinto the JFH-1genome. In vitro transcribed viral RNA was transfec-
ted into Huh-7 cells, and their replication was measured by north-
ern blotting. All three mutants revealed viral RNA levels that
increased by 30–60% compared to those of JFH-1 (Fig. 2A). In addi-
tion, a greater increase in NS5A expression was found in the K23E/
V31A mutant (Fig. 2B). However, the mutant viruses produced a
viral titer that increased only marginally compared to that of
JFH-1 (Fig. 2C). The small increase in the titer despite enhanced
genome replication and gene expression suggested that the core
mutations did not signiﬁcantly affect the assembly and/or release
of viral particles.
3.3. Modulation of the interferon pathways by the core proteins
Although the V31A mutation caused the antigenic escape of
the core protein, it was unlikely that the antibody response pro-
vided a selective advantage for the core mutants in cell culture.
As an alternative, we determined whether the type I IFN path-
ways were modulated by the core mutation. A luciferase reporter
gene, which was controlled by the IFN-b or ISRE promoters, was
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ter activity was measured. Compared to the cells that were trans-
fected with a replication-deﬁcient viral RNA (GND), the cells
transfected with JFH-1 RNA demonstrated increased reporter
activity, whereas no or weak activation was seen by the core mu-
tants (Fig. 3A). To address the effect of the core proteins without
the inﬂuence of viral RNA and other proteins, a reporter gene was
co-transfected with only the core genes. The reporter assay indi-
cated no activation of the IFN-b promoter and weak activation of
the ISRE promoter by the core. However, the effect of the core
was clearly evident with the co-expression of TBK1, an important
mediator of the type I IFN pathway. The JFH-1 core stimulated the
activation of IFN-b and ISRE promoters approximately twofold by
TBK1, whereas the V31A and K23E/V31A mutants demonstrated
no stimulatory effect, and the K23E mutation weakly stimulated
the promoters (Fig. 3B and C). A similar pattern was observed
for the core mutants in the activation of IFN promoters by IKKe
(data not shown). TBK1 and IKKe are the primary kinases that
mediate the IFN signaling downstream of RIG-I [25,26]. These re-
sults suggested that the ability of the core to stimulate the IFN
pathway had been attenuated by the mutations. We have con-
ﬁrmed by immunoblotting that the core proteins were expressed
at a similar level in these experiments to ensure that the ob-
served activity was not due to the difference in the amount of
core protein (not shown).
3.4. Interaction of the core with DDX3
We considered DDX3 to be a potential target of the core because
the IFN-modulatory effect of the core was more evident with TBK1
and IKKe, which work downstream of the pathway, and DDX3 was
known to modulate the IFN pathway through the interaction with
these kinases [19]. The interaction between DDX3 and the N-ter-
J.-I. Kang et al. / FEBS Letters 586 (2012) 1272–1278 1277minal domain of the core is known [16]. We hypothesized that
DDX3 may bind to the core mutants with different afﬁnity. This
possibility was addressed by a pull-down assay. The HaloTag-fused
core was precipitated from the extract of cells that co-express core
and DDX3, and the precipitant was assayed for DDX3 by immuno-
blotting. Compared to the JFH-1 core that co-precipitated with
DDX3, a small amount of DDX3 was co-puriﬁed with the core mu-
tants (Fig. 4A). The differential binding of DDX3 with the mutant
cores was quantitatively assessed in a mammalian two-hybrid as-
say. As indicated by the reporter activity, the afﬁnity of the three
core mutants for DDX3 was much weaker than that of the JFH-1
core (Fig. 4B). In addition, we examined whether the core and
DDX3 co-localized in the cells. In the transfected cells, DDX3 was
diffusely localized in the cytoplasm. The co-expression of the
JFH-1 core changed the DDX3 pattern into a more condensed dis-
tribution in the area that surrounded the nucleus. In contrast, the
K23E/V31A and V31A cores were distributed more diffusively in
the cytoplasm with apparently no co-localization with DDX3,
whereas the K23E partially co-localized with DDX3 in the perinu-
clear area (Fig. 5). This result is consistent with the result from the
pull-down and two-hybrid assays, which suggested that DDX3 was
bound and sequestered by the JFH-1 core as reported, whereas the
interaction was weakened or abrogated with the core mutants.
3.6. Membrane association of the core and DDX3
The majority of the core protein is associated with lipid droplet-
associated cellular membranes where particle assembly occurs
[27]. We examined whether a core mutation affects membrane
association of the core proteins. The immunoblot analysis of the
detergent-treated fractions revealed no differences among the core
mutants in their association with mainly detergent-insoluble
membrane fractions. A major portion of DDX3 was found in the
insoluble fraction with the co-expression of the JFH-1 core, which
is consistent with the sequestration of DDX3 by the core into the
insoluble membrane complex. Likewise, insoluble DDX3 was in-
creased with the co-expression of the core mutants; however,
the increase was signiﬁcantly less than that with the JFH-1 core
(Fig. 6A). It was not surprising that the membrane association of
the core mutants was not altered, because the D2 domain at the
C-terminus of the core is responsible for this association [28].
The differential association of DDX3 with the core was also demon-
strated in a membrane ﬂoatation assay. Compared to the JFH-1
core, the K23E/V31A core recruited a smaller amount of DDX3 into
the membrane-rich, low-density fractions (Fig. 6B). Collectively,
these results suggested that a core mutation does not affect mem-
brane association of the core but affects the DDX3 pattern through
differential interaction with DDX3.4. Discussion
The HCV core is considered to be essential in the encapsidation
of viral RNA and the assembly of virions [29]. Thus, a mutation in
the critical residue of the core is likely to affect viral infectivity. The
adapted core mutants that we found in this study did not indicate
any signiﬁcant effect on this aspect of viral replication. Rather, we
found that the core mutations modulated IFN signaling. We further
demonstrated that the IFN-modulating activity of the core mutants
correlated with their binding afﬁnity to DDX3, the cellular RNA
helicase that is implicated in the IFN pathways. We believe that
the enhanced genome replication of the adapted viruses is due to
the attenuating effect of the mutant core proteins on the activation
of the IFN responses through a differential interaction with DDX3.
DDX3 is an RNA helicase that activates IRF3 through an interac-
tion with TBK1/IKKe [19]. In previous studies, DDX3 was demon-strated to be required for HCV replication [17] and the DDX3
binding site was mapped at the N-terminus of the core [16]. How-
ever, the mutations at this region of the core that abrogated DDX3
binding had no effect on viral replication [18]. These ﬁndings sug-
gest that the interaction between DDX3 and the core is unrelated
to the essential role of DDX3 in viral replication; however, our re-
sults indicate that the core modulates DDX3 in IFN signaling. Re-
cently, it was shown that the core blocks DDX3 from interacting
with IPS-1 in the signaling for IFN-b [20]. Although the basis for
the difference between the results of the latter study and our study
is not clear, the activity of DDX3 in IFN signaling was modulated by
the core protein in both studies.
The triggering of the innate immune system by a virus can
either lead to the clearance of the virus or the establishment of a
persistent infection. As the ﬁrst viral protein synthesized during
HCV replication, activation of the IFN pathways by the core is con-
sidered a mechanism used by the virus to remain at a low steady-
state level of replication, which prevents the virus from being de-
tected by the host immune surveillance and facilitates persistent
infection. In the Los Alamos HCV Database we found several se-
quence ﬁles coding for the K23E and V31A core proteins, most of
which are from chronic HCV patients and some from experimen-
tally infected chimpanzees that had developed chronic infection
[30]. The differential modulation of IFN pathway depending on
the core protein quasi-species as observed in our study might have
contributed to the establishment of persistent infection.
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